Wang Jie, Cen Panpan, Chen Jiajia, Fan Linxiao, Li Jun, Cao Hongcui, Li Lanjuan
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University, 79 Qingchun Road, Hangzhou, 310006, China.
Stem Cell Res Ther. 2017 Jun 6;8(1):137. doi: 10.1186/s13287-017-0576-4.
Liver failure is a severe clinical syndrome with a poor prognosis. Mesenchymal stem cell (MSC) transplantation has emerged as a new intervention in treating liver failure. It is conventionally recognized that MSCs exert their therapeutic effect mainly through transdifferentiation. Recently, published articles have shown that MSCs work in liver failure by secreting trophic and immunomodulatory factors as well as extracellular vesicles (EVs) before transdifferentiation. In particular,MSC-derived EVs have shown similar curative effects as MSCs. Here we review the role of MSCs as well as their derived factors and EVs in liver failure and discuss the use of MSC-derived EVs instead of intact MSCs in treating liver failure.
肝衰竭是一种预后较差的严重临床综合征。间充质干细胞（MSC）移植已成为治疗肝衰竭的一种新干预措施。传统上认为，间充质干细胞主要通过转分化发挥其治疗作用。最近，已发表的文章表明，间充质干细胞在转分化之前通过分泌营养和免疫调节因子以及细胞外囊泡（EVs）来治疗肝衰竭。特别是，源自间充质干细胞的细胞外囊泡已显示出与间充质干细胞相似的治疗效果。在此，我们综述了间充质干细胞及其衍生因子和细胞外囊泡在肝衰竭中的作用，并讨论了使用源自间充质干细胞的细胞外囊泡而非完整的间充质干细胞来治疗肝衰竭。
